Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy
Study demonstrated statistically significant improvements in the overall study population with Type 2 or 3 SMA
No treatment related safety findings leading to withdrawal seen in any risdiplam trial to date
Data will be shared with health authorities globally, including the U.S. Food and Drug Administration (FDA)
Clinical Trail
NCT02908685
One reply on “Pivotal-SUNFISH study of Risdiplam (RG7916) continues to show significant improvement in patients with type 2/3 spinal muscular atrophy”
Risdiplam showed significant improvement in adults with SMA type 2,3